Welche Phytotherapeutika werden in medizinischen Leitlinien zur Behandlung gastroenterologischer Erkrankungen berücksichtigt?* 

Zusammenfassung

Die zunehmende Beliebtheit und wachsende Wirksamkeitsevidenz führen dazu, dass Phytotherapeutika vermehrt in medizinische Leitlinien integriert werden. Entsprechend der aktuellen wissenschaftlichen Datenlage werden gerade bei gastroenterologischen Erkrankungen einige Empfehlungen für die Anwendung von Phytotherapeutika ausgesprochen. Phytotherapeutika wie Pfefferminzöl oder Kümmelölauflagen werden beispielsweise beim Reizdarmsyndrom zur Symptomlinderung empfohlen. Bei chronischer Obstipation und Colitis ulcerosa werden Ballaststoffe wie Flohsamen empfohlen. Bei Colitis ulcerosa kann die Kombination von Myrrhe, Kamillenblütenextrakt und Kaffeekohle komplementär in der remissionserhaltenden Behandlung eingesetzt werden. Einige Phytotherapeutika (z.B. Wermut [Artemisia absinthium], Weihrauch [Boswellia serrata]) zeigen Wirksamkeitshinweise zur Behandlung von Morbus Crohn, jedoch ist die Datenlage noch nicht ausreichend für Empfehlungen. Einige klare Empfehlungen für den Einsatz von Phytotherapeutika zur Behandlung gastroenterologischer Erkrankungen zeigen ihr großes Wirkspektrum. Aufgrund ihrer zusätzlich hohen Verträglichkeit können sie sehr gut komplementär zu herkömmlichen Medikamenten eingesetzt werden. Dennoch sind weitere qualitativ hochwertige Wirkungsstudien für weitere Empfehlungen erforderlich.

Abstract

There is increasing popularity and growing evidence of efficacy of phytotherapeutics which is a pointer to their increasing integration into medical guidelines. Based on current scientific data, a number of recommendations for the use of phytotherapeutics are under consideration, particularly for gastroenterological diseases. As examples, phytotherapeutics such as peppermint oil or caraway oil are recommended for symptom relief in irritable bowel syndrome. Similarly dietary fibre such as psyllium husks are recommended for chronic constipation and ulcerative colitis. With regard to ulcerative colitis, the combination of myrrh, chamomile flower extract and coffee charcoal can be used as complementary treatment to maintain remission. Some phytotherapeutics, e. g. wormwood (Artemisia absinthium, herba), frankincense (Boswellia serrata, resina) exhibit indications of efficacy in the treatment of Crohn’s disease. However, there is hitherto insufficient data for reliable recommendations. Nonetheless, there are some clearer recommendations for the use of phytotherapeutics in the treatment of gastroenterological diseases with a broad spectrum of efficacy. The high tolerability of such drugs makes them an appropriate complement to conventional medications. However, there is need for more high-quality efficacy research in order to offer further targeted recommendations.

Schlüsselwörter

Leitlinien - gastroenterologische Erkrankungen - Phytotherapie - Phytopharmaka - pflanzliche Arzneimittel

Key words

Guidelines - gastroenterological diseases - phytotherapy - phytopharmaceuticals - herbal medicines

Publication History

Article published online:
04 December 2024

• Literatur

• 1 Schnabel K, Binting S, Witt CM, Teut M. Use of complementary and alternative medicine by older adults – A cross-sectional survey. BMC Geriatr 2014; 14: 38
• 2 Italia S, Brand H, Heinrich J. et al. Utilization of complementary and alternative medicine (CAM) among children from a German birth cohort (GINIplus): patterns, costs, and trends of use. BMC Complement Altern Med 2015; 15: 49
• 3 Müller I. Die pflanzlichen Heilmittel bei Hildegard von Bingen. Heilwissen aus der Klostermedizin. Salzburg 1982; Neudruck, 2. Aufl. Freiburg im Breisgau/Basel/Wien: Herder; 1993
• 4 Diepgen P, Goerke H. Kurze Übersichtstabelle zur Geschichte der Medizin. 7. Aufl. Berlin/Göttingen/Heidelberg: Springer; 1960. 21.
• 5 Statista. Apothekenumsatz mit rezeptfreien, homöopathischen und pflanzlichen Arzneimitteln 2023. Im Internet: https://de.statista.com/statistik/daten/studie/238427/umfrage/apothekenumsatz-mit-rezeptfreien-homoeopathischen-und-pflanzlichen-arzneimitteln/
• 6 Statista. Phytopharmaka – Top 10 der umsatzstärksten Indikationsgruppen von Phytopharmaka auf dem deutschen Apothekenmarkt 2023. Im Internet: https://de.statista.com/statistik/daten/studie/526054/umfrage/top-10-der-umsatzstaerksten-indikationsgruppen-von-phytopharmaka/
• 7 Utz S, Bittel M, Langhorst J. Phytotherapeutische Empfehlungen in medizinischen Leitlinien zur Behandlung gastroenterologischer Erkrankungen – ein systematischer Überblick. Z Gastroenterol 2024; 62: 1060-1073
• 8 DGVS & AWMF. S3-Leitlinie: Diagnostik und Therapie des Morbus Crohn – Version: 5.0. AWMF-Register-Nr.: 021-004, Stand: 01.08.2021. Im Internet: https://register.awmf.org/de/leitlinien/detail/021-004
• 9 DGVS & AWMF. S3-Leitlinie: Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs – Version: 2.0. AWMF-Register-Nr.: 032-009OL, Stand: 31.08.2019. Im Internet: https://register.awmf.org/de/leitlinien/detail/032-009OL
• 10 DGVS, DGNM & AWMF. S3-Leitlinie: Definition, Pathophysiologie, Diagnostik und Therapie des Reizdarmsyndroms – Version: 2.3. AWMF-Register-Nr.: 021-016, Stand: 31.03.2021. Im Internet: https://register.awmf.org/de/leitlinien/detail/021-016
• 11 DGVS & AWMF. S3-Leitlinie: Kolorektales Karzinom – Version: 2.1. AWMF-Register-Nr.: 021-007OL, Stand: 01.2019. Im Internet: https://register.awmf.org/de/leitlinien/detail/021-007OL
• 12 Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014; 48: 505-512
• 13 Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci 2016; 61: 560-571
• 14 Merat S, Khalili S, Mostajabi P. et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55: 1385-1390
• 15 Liu JP, Yang M, Liu YX. et al. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2006: CD004116
• 16 Shi J, Tong Y, Shen JG. et al. Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review. World J Gastroenterol 2008; 14: 454-462
• 17 Chen C, Tao C, Liu Z. et al. A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Phytother Res 2015; 29: 1822-1827
• 18 Sallon S, Ben-Arye E, Davidson R. et al. A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion 2002; 65: 161-171
• 19 Lauche R, Janzen A, Ludtke R. et al. Efficacy of Caraway Oil Poultices in Treating Irritable Bowel Syndrome – A Randomized Controlled Cross-Over Trial. Digestion 2015; 92: 22-31
• 20 Madisch A, Holtmann G, Plein K. et al. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004; 19: 271-279
• 21 Bortolotti M, Porta S. Effect of red pepper on symptoms of irritable bowel syndrome: preliminary study. Dig Dis Sci 2011; 56: 3288-3295
• 22 Brinkhaus B, Hentschel C, Von Keudell C. et al. Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Scand J Gastroenterol 2005; 40: 936-943
• 23 Davis K, Philpott S, Kumar D. et al. Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. Int J Clin Pract 2006; 60: 1080-1086
• 24 Ko SJ, Han G, Kim SK. et al. Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Evid Based Complement Alternat Med 2013; 2013: 824605
• 25 Lauche R, Kumar S, Hallmann J. et al. Efficacy and safety of Ayurvedic herbs in diarrhoea-predominant irritable bowel syndrome: A randomised controlled crossover trial. Complement Ther Med 2016; 26: 171-177
• 26 Van Tilburg MAL, Palsson OS, Ringel Y. et al. Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. Complement Ther Med 2014; 22: 17-20
• 27 Saito YA, Rey E, Almazar-Elder AE. et al. A randomized, double-blind, placebo-controlled trial of St John’s wort for treating irritable bowel syndrome. Am J Gastroenterol 2010; 105: 170-177
• 28 Oka T, Okumi H, Nishida S. et al. Effects of Kampo on functional gastrointestinal disorders. Biopsychosoc Med 2014; 8: 5
• 29 Zhang W, Sun JH, Pei LX. et al. Traditional Chinese medicine for treatment of irritable bowel syndrome: An overview of systematic reviews and metaanalyses. World Chin J Dig 2014; 22: 1747-1755
• 30 Longstreth GF, Thompson WG, Chey WD. et al. Functional bowel disorders. Gastroenterol 2006; 130: 1480-1491
• 31 DGVS, DGNM & AWMF. Aktualisierte S2k-Leitlinie chronische Obstipation – Version: 2.0. AWMF-Register-Nr.: 021-019, Stand: 30.10.2021. Im Internet: https://register.awmf.org/de/leitlinien/detail/021-019
• 32 Ashraf W, Park F, Lof J, Quigley EM. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther 1995; 9: 639-647
• 33 Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther 2011; 33: 895-901
• 34 Fenn GC, Wilkinson PD, Lee CE, Akbar FA. A general practice study of the efficacy of Regulan in functional constipation. Br J Gen Pract 1986; 40: 192-197
• 35 Nunes FP, Nunes CP, Levis E. et al. A double-blind trial of a celandin, aloe vera and psyllium laxative preparation in adult patients with constipation. Rev Bras Med 2005; 62: 352-357
• 36 Bove A, Bellini M, Battaglia E. et al. Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment). World J Gastroenterol 2012; 18: 4994-5013
• 37 Mueller-Lissner SA, Wald A. Constipation in adults. BMJ Clin Evid 2010; 2010: 0413
• 38 EFSA Panel on Dietetic Products N, Allergies. Scientific Opinion on the substantiation of a health claim related to hydroxyanthracene derivatives and improvement of bowel function pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2013; 11: 3412
• 39 Müller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta analysis. Br Med J (Clin Res Ed) 1988; 296: 615-617
• 40 Xu L, Yu W, Jiang J. et al. Clinical benefits after soluble dietary fiber supplementation: a randomized clinical trial in adults with slow-transit constipation. Zhonghua Yi Xue Za Zhi 2014; 94: 3813-3816
• 41 Hirose T, Shinoda Y, Kuroda A. et al. Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects. Int J Chronic Dis 2018; 2018: 1296717
• 42 Tsuda H, Kotani T, Sumigama S. et al. Efficacy and safety of daikenchuto (TJ-100) in pregnant women with constipation. Taiwan J Obstet Gynecol 2016; 55: 26-29
• 43 Iturrino J, Camilleri M, Wong BS. et al. Randomised clinical trial: the effects of daikenchuto, TU-100, on gastrointestinal and colonic transit, anorectal and bowel function in female patients with functional constipation. Aliment Pharmacol Ther 2013; 37: 776-785
• 44 Gong H, Qin F, He H. Herbal Formula Modified Buzhong-Yiqi-Tang for Functional Constipation in Adults: A Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med 2018; 2018: 9602525
• 45 Bensoussan A, Kellow JE, Bourchier SJ. et al. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial. Clin Gastroenterol Hepatol 2015; 13: 1946-1954
• 46 Zhong LLD, Cheng CW. KunWet al. Efficacy of MaZiRenWan, a Chinese Herbal Medicine, in Patients With Functional Constipation in a Randomized Controlled Trial. Clin Gastroenterol Hepatol 2019; 17: 1303-1310
• 47 Cheng CW, Bian ZX, Zhu LX. et al. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol 2011; 106: 120-129
• 48 Bian ZX, Cheng CW, Zhu LZ. Chinese herbal medicine for functional constipation: a randomised controlled trial. Hong Kong Med J 2013; 19: 44-46
• 49 Huang CH, Lin JS, Li TC. et al. Comparison of a Chinese Herbal Medicine (CCH1) and Lactulose as First-Line Treatment of Constipation in Long- Term Care: A Randomized, Double-Blind, Double-Dummy, and Placebo-Controlled Trial. Evid Based Complement Alternat Med 2012; 2012: 923190
• 50 Huang CH, Su YC, Li TC. et al. Treatment of constipation in long-term care with Chinese herbal formula: a randomized, double-blind placebo controlled trial. J Altern Complement Med 2011; 17: 639-646
• 51 DGVS & AWMF. S3-Leitlinie: Colitis ulcerosa – Version: 6.1. AWMF-Register-Nr.: 021-009, Stand: 26.04.2021. Im Internet: https://register.awmf.org/de/leitlinien/detail/021-009
• 52 Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL. et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94: 427-433
• 53 Langhorst J, Varnhagen I, Schneider SB. et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis–a double-blind, double-dummy study. Aliment Pharmacol Ther 2013; 38: 490-500
• 54 Langhorst J, Lauche R, Koch AK. Myrrhe, Kamille und Kaffeekohle in der Therapie von Patienten mit Colitis ulcerosa. Eine retrospektive Kohortenstudie mit 5-Jahres-Follow-up. Z Phytother 2016; 37: 249-253
• 55 Albrecht U, Muller V, Schneider B. et al. Efficacy and safety of a herbal medicinal product containing myrrh, chamomile and coffee charcoal for the treatment of gastrointestinal disorders: a non-interventional study. BMJ Open Gastroenterol 2014; 1: e000015
• 56 Hanai H, Iida T, Takeuchi K. et al. Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Clin Gastroenterol Hepatol 2006; 4: 1502-1506
• 57 Singla V, Pratap Mouli V, Garg SK. et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis – a randomized, placebo-controlled, pilot study. J Crohns Colitis 2014; 8: 208-214
• 58 Lang A, Salomon N, Wu JCY. et al. Curcumin in Combination with Mesalamine Induces Remission in Patients with Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol 2015; 13: 1444-1449
• 59 Kamali M, Tavakoli H, Khodadoost M. et al. Efficacy of the Punica granatum peels aqueous extract for symptom management in ulcerative colitis patients. A randomized, placebo-controlled, clinical trial. Complement Ther Clin Pract 2015; 21: 141-146
• 60 Gupta I, Parihar A, Malhotra P. et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997; 2: 37-43
• 61 Gupta I, Parihar A, Malhotra P. et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001; 67: 391-395
• 62 Tang T, Targan SR, Li ZS. et al. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 2011; 33: 194-202
• 63 Sandborn WJ, Targan SR, Byers VS. et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013; 108: 90-98
• 64 Ben-Arye E, Goldin E, Wengrower D. et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 2002; 37: 444-449
• 65 Rastegarpanah M, Malekzadeh R, Vahedi H. et al. A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis. Chin J Integr Med 2015; 21: 902-906
• 66 Tong ZQ, Yang B, Chen BY. et al. A multi-center, randomized, single-blind, controlled clinical study on the efficacy of composite sophora colon-soluble capsules in treating ulcerative colitis. Chin J Integr Med 2010; 16: 486-492
• 67 Biedermann L, Mwinyi J, Scharl M. et al. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis – an open pilot study. J Crohns Colitis 2013; 7: 271-279
• 68 Omer B. et al. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn’s disease: a double-blind placebo-controlled study. Phytomedicine 2007; 14: 87-95
• 69 Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn’s disease – A controlled clinical trial. Phytomedicine 2010; 17: 305-309
• 70 Gerhardt H, Seifert F. et al. Therapie des aktiven Morbus Crohn mit dem Boswellia-serrata-Extrakt H 15. Z Gastroenterol 2001; 39: 11-17
• 71 Holtmeier W. et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 2011; 17: 573-582
• 72 Kafil TS. et al. Cannabis for the treatment of Crohn’s disease. Cochrane Database Syst Rev 2018; 11: CD012853
• 73 Dahm CC. et al. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries. J Natl Cancer Inst 2010; 102: 614-626
• 74 Ishikawa H. et al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 2005; 116: 762-767
• 75 Jacobs ET. et al. Fiber, sex, and colorectal adenoma: results of a pooled analysis. Am J Clin Nutr 2006; 83: 343-349
• 76 Park Y. et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 2005; 294: 2849-2857
• 77 Robertson DJ. et al. Fat, fiber, meat and the risk of colorectal adenomas. Am J Gastroenterol 2005; 100: 2789-2795
• 78 Stumpf C, Rieger S. et al. Retrospektive Untersuchung zur Therapie mit Mistelextrakten bei Patienten mit kolorektalem Karzinom. Dtsch Zschr Onkol 2007; 39: 12-22
• 79 Friedel W. et al. Fermented Europaen mistletoe (Viscum album L.) extract in supportive care in patients with primary non-metastatic colorectal cancer. In: Scheer R et al., Hrsg. Die Mistel in der Tumortherapie 2. Essen: KVC-Verlag; 2009: 563-576
• 80 Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 2010; 9: 142-157
• 81 Shimizu M. et al. (–)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res (Phila) 2008; 1: 298-304
• 82 Hoensch H. et al. Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. World J Gastroenterol 2008; 14: 2187-2193
• 83 Ito K. et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis 2004; 19: 157-164
• 84 Sakamoto J. et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 2006; 55: 404-411
• 85 Kim KC. et al. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma – a randomized, controlled pilot study. BMC Complement Altern Med 2012; 12: 172
• 86 Horneber MA. et al. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008; 2: CD003297
• 87 Ostermann T, Büssing A. Retrolective Studies on the Survival of Cancer Patients Treated With Mistletoe Extracts: A Meta-analysis. Explore: J Sci Heal 2012; 8: 277-281
• 88 Ostermann T, Raak C, Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer 2009; 9: 451
• 89 Kleeberg UR. et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness>3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40: 390-402
• 90 Steuer-Vogt MK, Bonkowsky V, Scholz M. et al. Einfluss eines ML-1-normierten Mistelextraktes auf die Lebensqualität bei Patienten mit Kopf-Hals-Karzinomen. HNO 2006; 54: 277-286
• 91 Yang J. et al. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev 2013; 4: CD005096
• 92 Tascilar M. et al. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006; 11: 732-741
• 93 Bittel M, Rakoczy T, Fröhlich A, Langhorst J. Phytotherapie bei psychischen Erkrankungen in medizinischen Leitlinien. Z Phytother 2022; 43: 112-120